Gastric cancer

Critical Reviews in Oncology/Hematology

Volumn 71, Issue 2, 2009, Pages 127-164

  Catalano, Vincenzo ^a   Labianca, Roberto ^b   Beretta, Giordano D ^c   Gatta, Gemma ^d   de Braud, Filippo ^e   Van Cutsem, Eric ^f  

^a SAN SALVATORE HOSPITAL   (Italy)

^b OSPEDALI RIUNITI   (Italy)

^c S Orsola Hospital   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Chemotherapy; Gastric cancer; Management; Treatment

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CAPECITABINE; CARMUSTINE; CETUXIMAB; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; GLUTATHIONE; IRINOTECAN; KRESTIN; LEVAMISOLE; METHOTREXATE; MITOMYCIN C; NITROSOUREA; OXALIPLATIN; PICIBANIL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SEMUSTINE; THIOTEPA; UFT;

ABDOMINAL ABSCESS; ALOPECIA; ANEMIA; ANOREXIA; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER GRADING; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTRAST ENHANCEMENT; DIAGNOSTIC APPROACH ROUTE; DIARRHEA; DIETARY INTAKE; DIGESTIVE SYSTEM PERFORATION; DISEASE MARKER; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG FATALITY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EARLY DIAGNOSIS; FATIGUE; FEBRILE NEUTROPENIA; GASTRECTOMY; GASTROINTESTINAL DYSPLASIA; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SURGERY; HAND FOOT SYNDROME; HELICOBACTER INFECTION; HISTOGENESIS; HISTOPATHOLOGY; HUMAN; HYPERTENSION; LETHARGY; LEUKOPENIA; LYMPHADENECTOMY; MASS SCREENING; METASTASIS; MIGRATION; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; PANCREAS RESECTION; PERIPHERAL NEUROPATHY; PREOPERATIVE EVALUATION; PREVALENCE; PROGNOSIS; QUALITY OF LIFE; REVIEW; RISK FACTOR; SMOKING; SPLENECTOMY; STOMACH CANCER; STOMATITIS; SYMPTOMATOLOGY; THROMBOCYTOPENIA; THROMBOEMBOLISM; VOMITING;

ANTIMETABOLITES, ANTINEOPLASTIC; HUMANS; NEOPLASM STAGING; PALLIATIVE CARE; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 67649449102     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2009.01.004     Document Type: Review

References (406)

1. Ferlay J., Bray F., Pisani P., and Parkin D.M. GLOBOCAN 2002 cancer incidence, mortality and prevalence worldwide. IARC cancerbase no. 5, version 2.0 (2004), IARC Press, Lyon
2. Correa P., and Chen V.W. Gastric cancer. Cancer Surv 19-20 (1994) 55-76
3. Aragones N., Pollan M., Rodero I., and Lopez-Abente G. Gastric cancer in the European Union (1968-1992): mortality trends and cohort effect. Ann Epidemiol 7 (1997) 294-303
4. Ferretti S., and Gafa L. Upper gastrointestinal tract cancers: oesophagus, stomach, liver, gallbladder and biliary ducts, pancreas. Epidemiol Prev 28 (2004) 34-42
5. Kelley J.R., and Duggan J.M. Gastric cancer epidemiology and risk factors. J Clin Epidemiol 56 (2003) 1-9
6. Devesa S.S., Blot W.J., and Fraumeni Jr. J.F. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83 (1998) 2049-2053
7. Powell J., and McConkey C.C. Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites. Br J Cancer 62 (1990) 440-443
8. Liu Y., Kaneko S., and Sobue T. Trends in reported incidences of gastric cancer by tumour location, from 1975 to 1989 in Japan. Int J Epidemiol 33 (2004) 808-815
9. Kaneko S., and Yoshimura T. Time trend analysis of gastric cancer incidence in Japan by histological types, 1975-1989. Br J Cancer 84 (2001) 400-405
10. El-Serag H.B., Mason A.C., Petersen N., and Key C.R. Epidemiological differences between adenocarcinoma of the oesophagus and adenocarcinoma of the gastric cardia in the USA. Gut 50 (2002) 368-372
11. Parkin D.M., Whelan S.L., and Ferlay J. Cancer incidence in five continents vol VII (1997), International Agency for Research on Cancer, Lyon, France p. 822-3
12. Jemal A., Thomas A., Murray T., and Thun M. Cancer statistics, 2002. CA Cancer J Clin 52 (2002) 23-47
13. Ries L.A., Kosary C.L., and Hankey B.F. SEER cancer statistics review 1973-1995 (1998), U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute, Bethesda
14. Verdecchia A., Corazziari I., Gatta G., Lisi D., Faivre J., and Forman D. Explaining gastric cancer survival differences among European countries. Int J Cancer 109 (2004) 737-741
15. Fielding J.W.L., Powell J., and Allum W.H. Cancer of the stomach (1989), The Macmillan Press, London
16. Faivre J., Forman D., Esteve J., and Gatta G. Survival of patients with oesophageal and gastric cancers in Europe. Eur J Cancer 34 (1998) 2167-2175
17. Berrino F, Capocaccia R, Esteve J. Survival of cancer patients in Europe: the EUROCARE-2 study. IARC Scientific Publications No. 151. Lyon: IARC; 1999.
18. Verdecchia A., Francisci S., Brenner H., et al. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 8 (2007) 784-796
19. Verdecchia A., Mariotto A., Gatta G., Bustamante-Teixeira M.T., and Ajiki W. Comparison of stomach cancer incidence and survival in four continents. Eur J Cancer 39 (2003) 1603-1609
20. Micheli A., Mugno E., Krogh V., et al. Cancer prevalence in European registry areas. Ann Oncol 13 (2002) 840-865
21. Kolonel L.N., Nomura A.M., Hirohata T., Hankin J.H., and Hinds M.W. Association of diet and place of birth with stomach cancer incidence in Hawaii Japanese and Caucasians. Am J Clin Nutr 34 (1981) 2478-2485
22. Nomura A. Stomach cancer. In: Scottenfeld D., and Fraumeni J.F. (Eds). Cancer epidemiology and prevention. 2nd edition (1996), Oxford University press, New York 707-724
23. Coggon D., Osmond C., and Barker D.J. Stomach cancer and migration within England and Wales. Br J Cancer 61 (1990) 573-574
24. WCRF & AICR. Food, nutrition, physical activity and the prevention of cancer: a global perspective (2007), AICR, Washington, DC
25. Gonzalez C.A., Pera G., Agudo A., et al. Smoking and the risk of gastric cancer in the European prospective investigation into cancer and nutrition (EPIC). Int J Cancer 107 (2003) 629-634
26. Sjodahl K., Lu Y., Nilsen T.I., et al. Smoking and alcohol drinking in relation to risk of gastric cancer: a population-based, prospective cohort study. Int J Cancer 120 (2007) 128-132
27. Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 49 (2001) 347-353
28. Parsonnet J. The incidence of helicobacter pylori infection. Aliment Pharmacol Ther 9 Suppl 2 (1995) 45-51
29. Howson C.P., Hiyama T., and Wynder E.L. The decline in gastric cancer: epidemiology of an unplanned triumph. Epidemiol Rev 8 (1986) 1-27
30. Eslick G.D. Helicobacter pylori infection causes gastric cancer? A review of the epidemiological, meta-analytic, and experimental evidence. World J Gastroenterol 12 (2006) 2991-2999
31. Laheij R.J., Straatman H., Verbeek A.L., and Jansen J.B. Mortality trend from cancer of the gastric cardia in The Netherlands, 1969-1994. Int J Epidemiol 28 (1999) 391-395
32. Barber M., Fitzgerald R.C., and Caldas C. Familial gastric cancer-aetiology and pathogenesis. Best Pract Res Clin Gastroenterol 20 (2006) 721-734
33. Dhillon P.K., Farrow D.C., Vaughan T.L., et al. Family history of cancer and risk of esophageal and gastric cancers in the United States. Int J Cancer 93 (2001) 148-152
34. Miki K. Gastric cancer screening using the serum pepsinogen test method. Gastric Cancer 9 (2006) 245-253
35. Dinis-Ribeiro M., Yamaki G., Miki K., et al. Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening. J Med Screen 11 (2004) 141-147
36. Stemmermann G.N. Intestinal metaplasia of the stomach. A status report. Cancer 74 (1994) 556-564
37. Correa P., Haenszel W., Cuello C., Tannenbaum S., and Archer M. A model for gastric cancer epidemiology. Lancet 2 (1975) 58-60
38. Correa P. Clinical implications of recent developments in gastric cancer pathology and epidemiology. Semin Oncol 12 (1985) 2-10
39. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process-First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 52 (1992) 6735-6740
40. Noffsinger A., Stemmermann G.N., Kim O.J., and Fenoglio-Preiser C.M. Gastric cancer: pathology. In: Kelsen D.P., Daly J.M., Kern S.E., Levin B., and Tepper J.E. (Eds). Gastrointestinal oncology: principles and practice (2002), Lippincott Williams & Wilkins, Philadelphia 355-369
41. Goldstein N.S., and Lewin K.J. Gastric epithelial dysplasia and adenoma: historical review and histological criteria for grading. Hum Pathol 28 (1997) 127-133
42. Lansdown M., Quirke P., Dixon M.F., Axon A.T., and Johnston D. High grade dysplasia of the gastric mucosa: a marker for gastric carcinoma. Gut 31 (1990) 977-983
43. Borrmann R. Geschwulste des magens and duodenums. In: Henke F., and Lubarsch O. (Eds). Handbuch der speziellen pathologischen anatomie and histologie (1926), Springer-Verlag, Berlin 865
44. World Health Organization. Tumours of the stomach. In: Hamilton S.R., and Aaltonen L.A. (Eds). World Health Organization classification of tumours. Tumours of the digestive system (2000), IARC Press, Lyon 37-68
45. Lauren P. The two histological main types of gastric carcinoma: diffused and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 64 (1965) 31-49
46. Hermanek P., and Wittekind C. News of TNM and its use for classification of gastric cancer. World J Surg 19 (1995) 491-495
47. Ming S.C. Gastric carcinoma. A pathobiological classification. Cancer 39 (1977) 2475-2485
48. Hirota T., Ming S.C., and Itabashhi M. Pathology of early gastric cancer. In: Nishi M., Ichikawa H., Nakajima T., et al. (Eds). Gastric cancer (1993), Springer-Verlag, Tokyo 66-86
49. Murakami T. Pathomorphological diagnosis. Definition and gross classification of early gastric cancer. Gann Monogr 11 (1971) 53-55
50. Tsukuma H., Mishima T., and Oshima A. Prospective study of "early" gastric cancer. Int J Cancer 31 (1983) 421-426
51. Adachi Y., Mori M., and Sugimachi K. Persistence of mucosal gastric carcinomas for 8 and 6 years in two patients. Arch Pathol Lab Med 114 (1990) 1046-1048
52. Fenoglio-Preiser C.M., Noffsinger A.E., Belli J., and Stemmermann G.N. Pathologic and phenotypic features of gastric cancer. Semin Oncol 23 (1996) 292-306
53. Broder A.C. The grading of carcinoma. Minn Med 8 (1925) 726-730
54. White R.M., Levine M.S., Enterline H.T., and Laufer I. Early gastric cancer. Recent experience. Radiology 155 (1985) 25-27
55. Hallissey M.T., Allum W.H., Jewkes A.J., Ellis D.J., and Fielding J.W. Early detection of gastric cancer. BMJ 301 (1990) 513-515
56. Low V.H., Levine M.S., Rubesin S.E., Laufer I., and Herlinger H. Diagnosis of gastric carcinoma: sensitivity of double-contrast barium studies. AJR Am J Roentgenol 162 (1994) 329-334
57. Sakita T., Oguro Y., Takasu S., Fukutomi H., and Miwa T. Observations on the healing of ulcerations in early gastric cancer. The life cycle of the malignant ulcer. Gastroenterology 60 (1971) 835-839
58. Levine M.S. Peptic ulcers. In: Gore R.M., Levine M.S., and Laufer I. (Eds). Textbook of gastrointestinal radiology (1994), Saunders, Philadelphia 562-597
59. Halvorsen Jr. R.A., Yee J., and McCormick V.D. Diagnosis and staging of gastric cancer. Semin Oncol 23 (1996) 325-335
60. Winawer S.J., Posner G., Lightdale C.J., et al. Endoscopic diagnosis of advanced gastric cancer. Factors influencing yield. Gastroenterology 69 (1975) 1183-1187
61. Silvis S.E., Nebel O., Rogers G., Sugawa C., and Mandelstam P. Endoscopic complications. Results of the 1974 American society for gastrointestinal endoscopy survey. JAMA 235 (1976) 928-930
62. Dooley C.P., Larson A.W., Stace N.H., et al. Double-contrast barium meal and upper gastrointestinal endoscopy. A comparative study. Ann Intern Med 101 (1984) 538-545
63. Boyce G.A. Endoscopic evaluation of the patient with esophageal carcinoma. Chest Surg Clin N Am 4 (1994) 257-268
64. Kurihara M., Shirakabe H., Yarita T., et al. Diagnosis of small early gastric cancer by X-ray, endoscopy, and biopsy. Cancer Detect Prev 4 (1981) 377-383
65. Kurtz R.C., and Sherlock P. The diagnosis of gastric cancer. Semin Oncol 12 (1985) 11-18
66. Graham D.Y., Schwartz J.T., Cain G.D., and Gyorkey F. Prospective evaluation of biopsy number in the diagnosis of esophageal and gastric carcinoma. Gastroenterology 82 (1982) 228-231
67. Graham D.Y., Akdamar K., Dyck W.P., et al. Healing of benign gastric ulcer: comparison of cimetidine and placebo in the United States. Ann Intern Med 102 (1985) 573-576
68. Isenberg J.I., Peterson W.L., Elashoff J.D., et al. Healing of benign gastric ulcer with low-dose antacid or cimetidine. A double-blind, randomized, placebo-controlled trial. N Engl J Med 308 (1983) 1319-1324
69. Levine M.S., Creteur V., Kressel H.Y., Laufer I., and Herlinger H. Benign gastric ulcers: diagnosis and follow-up with double-contrast radiography. Radiology 164 (1987) 9-13
70. Kurtz R.C., and Ginsberg R.J. Cancer diagnosis: endoscopy. In: De Vita Jr. V., Hellman S., and Rosenberg S.A. (Eds). Cancer: principles and practice of oncology. 6th edition (2001), Lippincott Williams & Wilkins, Philadelphia 721-737
71. Sedgwick D.M., Akoh J.A., and Macintyre I.M. Gastric cancer in Scotland: changing epidemiology, unchanging workload. BMJ 302 (1991) 1305-1307
72. Witzel L., Halter F., Gretillat P.A., Scheurer U., and Keller M. Evaluation of specific value of endoscopic biopsies and brush cytology for malignancies of the oesophagus and stomach. Gut 17 (1976) 375-377
73. Qizilbash A.H., Castelli M., Kowalski M.A., and Churly A. Endoscopic brush cytology and biopsy in the diagnosis of cancer of the upper gastrointestinal tract. Acta Cytol 24 (1980) 313-318
74. Levine M.S., Rubesin S.E., Herlinger H., and Laufer I. Double-contrast upper gastrointestinal examination: technique and interpretation. Radiology 168 (1988) 593-602
75. Iishi H., Yamamoto R., Tatsuta M., and Okuda S. Evaluation of fine-needle aspiration biopsy under direct vision gastrofiberscopy in diagnosis of diffusely infiltrative carcinoma of the stomach. Cancer 57 (1986) 1365-1369
76. Rey J.F., and Lambert R. ESGE recommendations for quality control in gastrointestinal endoscopy: guidelines for image documentation in upper and lower GI endoscopy. Endoscopy 33 (2001) 901-903
77. Stadtlander C.T., and Waterbor J.W. Molecular epidemiology, pathogenesis and prevention of gastric cancer. Carcinogenesis 20 (1999) 2195-2208
78. Yasui W., Oue N., Kuniyasu H., et al. Molecular diagnosis of gastric cancer: present and future. Gastric Cancer 4 (2001) 113-121
79. Hakama M., Stenman U.H., Knekt P., et al. Tumour markers and screening for gastrointestinal cancer: a follow up study in Finland. J Med Screen 1 (1994) 60-64
80. Posner M.R., and Mayer R.J. The use of serologic tumor markers in gastrointestinal malignancies. Hematol Oncol Clin North Am 8 (1994) 533-553
81. Nakane Y., Okamura S., Akehira K., et al. Correlation of preoperative carcinoembryonic antigen levels and prognosis of gastric cancer patients. Cancer 73 (1994) 2703-2708
82. Pectasides D., Mylonakis A., Kostopoulou M., et al. CEA, CA 19-9, and CA-50 in monitoring gastric carcinoma. Am J Clin Oncol 20 (1997) 348-353
83. Green F.L., Page D.L., Fleming I.D., et al. AJCC cancer staging manual. 6th edition (2002), Springer, New York
84. International Union Against Cancer. In: Sobin L.H., and Wittekind Ch (Eds). TNM classification of malignant tumours. 6th ed. (2002), Wiley-Liss Book, New York, Chichester, Weinheim, Brisbane, Singapore, Toronto
85. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma-2nd english edition. Gastric Cancer 1 (1998) 10-24
86. Sasako M., McCulloch P., Kinoshita T., and Maruyama K. New method to evaluate the therapeutic value of lymph node dissection for gastric cancer. Br J Surg 82 (1995) 46-51
87. Dux M., Richter G.M., Hansmann J., Kuntz C., and Kauffmann G.W. Helical hydro-CT for diagnosis and staging of gastric carcinoma. J Comput Assist Tomogr 23 (1999) 913-922
88. Davies J., Chalmers A.G., Sue-Ling H.M., et al. Spiral computed tomography and operative staging of gastric carcinoma: a comparison with histopathological staging. Gut 41 (1997) 314-319
89. Adachi Y., Sakino I., Matsumata T., et al. Preoperative assessment of advanced gastric carcinoma using computed tomography. Am J Gastroenterol 92 (1997) 872-875
90. Takao M., Fukuda T., Iwanaga S., et al. Gastric cancer: evaluation of triphasic spiral CT and radiologic-pathologic correlation. J Comput Assist Tomogr 22 (1998) 288-294
91. Paramo J.C., and Gomez G. Dynamic CT in the preoperative evaluation of patients with gastric cancer: correlation with surgical findings and pathology. Ann Surg Oncol 6 (1999) 379-384
92. Tschmelitsch J., Weiser M.R., and Karpeh M.S. Modern staging in gastric cancer. Surg Oncol 9 (2000) 23-30
93. Fukuya T., Honda H., Hayashi T., et al. Lymph-node metastases: efficacy for detection with helical CT in patients with gastric cancer. Radiology 197 (1995) 705-711
94. Dux M., Roeren T., Kuntz C., Richter G.M., and Kauffmann G.W. TNM staging of gastrointestinal tumors by hydrosonography: results of a histopathologically controlled study in 60 patients. Abdom Imaging 22 (1997) 24-34
95. Rossi M., Broglia L., Maccioni F., et al. Hydro-CT in patients with gastric cancer: preoperative radiologic staging. Eur Radiol 7 (1997) 659-664
96. Sussman S.K., Halvorsen Jr. R.A., Illescas F.F., et al. Gastric adenocarcinoma: CT versus surgical staging. Radiology 167 (1988) 335-340
97. Isozaki H., Okajima K., Nomura E., et al. Preoperative diagnosis and surgical treatment for lymph node metastasis in gastric cancer. Gan To Kagaku Ryoho 23 (1996) 1275-1283
98. Pollack B.J., Chak A., and Sivak Jr. M.V. Endoscopic ultrasonography. Semin Oncol 23 (1996) 336-346
99. Dittler H.J., and Siewert J.R. Role of endoscopic ultrasonography in gastric carcinoma. Endoscopy 25 (1993) 162-166
100. Botet J.F., Lightdale C.J., Zauber A.G., et al. Preoperative staging of gastric cancer: comparison of endoscopic US and dynamic CT. Radiology 181 (1991) 426-432
101. Grimm H., Hamper K., Maydeo A., et al. Accuracy of endoscopic ultrasound and computed tomography in determining of local/regional spread of gastric cancer: results of a prospective controlled study. Gastrointest Endosc 37 (1991) 279 [abstract]
102. Gupta N., and Bradfield H. Role of positron emission tomography scanning in evaluating gastrointestinal neoplasms. Semin Nucl Med 26 (1996) 65-73
103. Roder J.D., Bottcher K., Busch R., et al. Classification of regional lymph node metastasis from gastric carcinoma. German Gastric Cancer Study Group. Cancer 82 (1998) 621-631
104. Burke E.C., Karpeh M.S., Conlon K.C., and Brennan M.F. Laparoscopy in the management of gastric adenocarcinoma. Ann Surg 225 (1997) 262-267
105. Stell D.A., Carter C.R., Stewart I., and Anderson J.R. Prospective comparison of laparoscopy, ultrasonography and computed tomography in the staging of gastric cancer. Br J Surg 83 (1996) 1260-1262
106. Bonavina L., Incarbone R., Lattuada E., et al. Preoperative laparoscopy in management of patients with carcinoma of the esophagus and of the esophagogastric junction. J Surg Oncol 65 (1997) 171-174
107. Conlon K.C., and Karpeh Jr. M.S. Laparoscopy and laparoscopic ultrasound in the staging of gastric cancer. Semin Oncol 23 (1996) 347-351
108. Cuschieri A. Role of video-laparoscopy in the staging of intra-abdominal lymphomas and gastrointestinal cancer. Semin Surg Oncol 20 (2001) 167-172
109. Parker S.L., Tong T., Bolden S., and Wingo P.A. Cancer statistics, 1997. CA Cancer J Clin 47 (1997) 5-27
110. Allum W.H., Powell D.J., McConkey C.C., and Fielding J.W. Gastric cancer: a 25-year review. Br J Surg 76 (1989) 535-540
111. Wanebo H.J., Kennedy B.J., Chmiel J., et al. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg 218 (1993) 583-592
112. Akoh J.A., and Macintyre I.M. Improving survival in gastric cancer: review of 5-year survival rates in English language publications from 1970. Br J Surg 79 (1992) 293-299
113. Hermanek P., Maruyama K., and Sobin L.H. Gastric cancer. In: Hermanek P., Gospodarowicz M.K., Henson D.E., Hutter R.V.P., and Sobin L.H. (Eds). Prognostic factors in cancer (1995), International Union Against Cancer (UICC), Geneve
114. Alexander H.R., Kelsen D., and Tepper J.C. Cancer of the stomach. In: De Vita V., Hellman S., and Rosenberg S. (Eds). Cancer: principles and practice of oncology. 5th edition (1997), JB Lippincott, Philadelphia 1021-1054
115. UICC (International Union Against Cancer). In: Sobin L.H., and Wittekind C.H. (Eds). TNM classification of malignant tumours. 5th edition (1997), Wiley-Liss, New York, Chichester, Weinheim, Brisbane, Singapore, Toronto
116. van Krieken J.H., Sasako M., and van de velde C.J. Gastric cancer. In: Gospodarowicz M.K., Henson D.E., Hutter R.V.P., O'Sullivan B., Sobin L.H., and Wittekind C. (Eds). Prognostic factors in cancer (2001), Wiley-Liss, New York 251-265
117. Rohde H., Gebbensleben B., Bauer P., Stutzer H., and Zieschang J. Has there been any improvement in the staging of gastric cancer? Findings from the German Gastric Cancer TNM Study Group. Cancer 64 (1989) 2465-2481
118. Carriaga M.T., and Henson D.E. The histologic grading of cancer. Cancer 75 (1995) 406-421
119. Bunt A.M., Hogendoorn P.C., van de Velde C.J., Bruijn J.A., and Hermans J. Lymph node staging standards in gastric cancer. J Clin Oncol 13 (1995) 2309-2316
120. Hartgrink H.H., Bonenkamp H.J., and van de Velde C.J. Influence of surgery on outcomes in gastric cancer. Surg Oncol Clin N Am 9 (2000) 91-117
121. Siewert J.R., Bottcher K., Stein H.J., and Roder J.D. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 228 (1998) 449-461
122. British Stomach Cancer Group. Resection line disease in stomach cancer. Br Med J (Clin Res Ed) 289 (1984) 601-603
123. Fujimoto S., Takahashi M., Mutou T., et al. Clinicopathologic characteristics of gastric cancer patients with cancer infiltration at surgical margin at gastrectomy. Anticancer Res 17 (1997) 689-694
124. Takagane A., Terashima M., Abe K., et al. Evaluation of the ratio of lymph node metastasis as a prognostic factor in patients with gastric cancer. Gastric Cancer 2 (1999) 122-128
125. Bollschweiler E., Boettcher K., Hoelscher A.H., et al. Is the prognosis for Japanese and German patients with gastric cancer really different?. Cancer 71 (1993) 2918-2925
126. Kikuchi S., Hiki Y., Shimao H., Sakakibara Y., and Kakita A. Tumor volume: a novel prognostic factor in patients who undergo curative resection for gastric cancer. Langenbecks Arch Surg 385 (2000) 225-228
127. Maehara Y., Kakeji Y., Oda S., et al. Time trends of surgical treatment and the prognosis for Japanese patients with gastric cancer. Br J Cancer 83 (2000) 986-991
128. Moriguchi S., Maehara Y., Korenaga D., Sugimachi K., and Nose Y. Relationship between age and the time of surgery and prognosis after gastrectomy for gastric cancer. J Surg Oncol 52 (1993) 119-123
129. Lo S.S., Kuo H.S., Wu C.W., et al. Poorer prognosis in young patients with gastric cancer?. Hepatogastroenterology 46 (1999) 2690-2693
130. Maguire A., Porta M., Sanz-Anquela J.M., et al. Sex as a prognostic factor in gastric cancer. Eur J Cancer 32A (1996) 1303-1309
131. Maehara Y., Watanabe A., Kakeji Y., et al. Prognosis for surgically treated gastric cancer patients is poorer for women than men in all patients under age 50. Br J Cancer 65 (1992) 417-420
132. Tachibana M., Takemoto Y., Nakashima Y., et al. Serum carcinoembryonic antigen as a prognostic factor in resectable gastric cancer. J Am Coll Surg 187 (1998) 64-68
133. Sakamoto J., Nakazato H., Teramukai S., et al. Association between preoperative plasma CEA levels and the prognosis of gastric cancer following curative resection. Tumor Marker Committee, Japanese Foundation for Multidisciplinary Treatment of Cancer, Tokyo, Japan. Surg Oncol 5 (1996) 133-139
134. Maehara Y., Kusumoto T., Takahashi I., et al. Predictive value of preoperative carcinoembryonic antigen levels for the prognosis of patients with well-differentiated gastric cancer. A multivariate analysis. Oncology 51 (1994) 234-237
135. Irinoda T., Terashima M., Takagane A., et al. Carcinoembryonic antigen level in peritoneal washing is a prognostic factor in patients with gastric cancer. Oncol Rep 5 (1998) 661-666
136. Nishiyama M., Takashima I., Tanaka T., et al. Carcinoembryonic antigen levels in the peritoneal cavity: useful guide to peritoneal recurrence and prognosis for gastric cancer. World J Surg 19 (1995) 133-137
137. Kampschoer G.H., Maruyama K., Sasako M., Kinoshita T., and van de Velde C.J. The effects of blood transfusion on the prognosis of patients with gastric cancer. World J Surg 13 (1989) 637-643
138. Becker K.F., Keller G., and Hoefler H. The use of molecular biology in diagnosis and prognosis of gastric cancer. Surg Oncol 9 (2000) 5-11
139. Fenoglio-Preiser C.M., Wang J., Stemmermann G.N., and Noffsinger A. TP53 and gastric carcinoma: a review. Hum Mutat 21 (2003) 258-270
140. Yamada Y., Yoshida T., Hayashi K., et al. p53 gene mutations in gastric cancer metastases and in gastric cancer cell lines derived from metastases. Cancer Res 51 (1991) 5800-5805
141. Correa P., and Shiao Y.H. Phenotypic and genotypic events in gastric carcinogenesis. Cancer Res 54 (1994) 1941s-1943s
142. Tahara E., Semba S., and Tahara H. Molecular biological observations in gastric cancer. Semin Oncol 23 (1996) 307-315
143. Kubicka S., Claas C., Staab S., et al. p53 mutation pattern and expression of c-erbB2 and c-met in gastric cancer: relation to histological subtypes, helicobacter pylori infection, and prognosis. Dig Dis Sci 47 (2002) 114-121
144. Maeda K., Kang S.M., Onoda N., et al. Expression of p53 and vascular endothelial growth factor associated with tumor angiogenesis and prognosis in gastric cancer. Oncology 55 (1998) 594-599
145. Fonseca L., Yonemura Y., De A.X., et al. p53 detection as a prognostic factor in early gastric cancer. Oncology 51 (1994) 485-490
146. Victorzon M., Nordling S., Haglund C., Lundin J., and Roberts P.J. Expression of p53 protein as a prognostic factor in patients with gastric cancer. Eur J Cancer 32A (1996) 215-220
147. Ichiyoshi Y., Oiwa H., Tomisaki S., et al. Overexpression of p53 is associated with growth pattern and prognosis in advanced gastric cancer. Hepatogastroenterology 44 (1997) 546-553
148. Xiangming C., Hokita S., Natsugoe S., et al. p21 expression is a prognostic factor in patients with p53-negative gastric cancer. Cancer Lett 148 (2000) 181-188
149. Araya M., Terashima M., Takagane A., et al. Microvessel count predicts metastasis and prognosis in patients with gastric cancer. J Surg Oncol 65 (1997) 232-236
150. Jonjic N., Kovac K., Krasevic M., et al. Epidermal growth factor-receptor expression correlates with tumor cell proliferation and prognosis in gastric cancer. Anticancer Res 17 (1997) 3883-3888
151. Takano Y., Kato Y., van Diest P.J., et al. Cyclin D2 overexpression and lack of p27 correlate positively and cyclin E inversely with a poor prognosis in gastric cancer cases. Am J Pathol 156 (2000) 585-594
152. Wu M.S., Lee C.W., Sheu J.C., et al. Alterations of BAT-26 identify a subset of gastric cancer with distinct clinicopathologic features and better postoperative prognosis. Hepatogastroenterology 49 (2002) 285-289
153. Nekarda H., Schmitt M., Ulm K., et al. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res 54 (1994) 2900-2907
154. Okusa Y., Ichikura T., and Mochizuki H. Prognostic impact of stromal cell-derived urokinase-type plasminogen activator in gastric carcinoma. Cancer 85 (1999) 1033-1038
155. Saito H., Tsujitani S., Ikeguchi M., Maeta M., and Kaibara N. Serum level of a soluble receptor for interleukin-2 as a prognostic factor in patients with gastric cancer. Oncology 56 (1999) 253-258
156. Maeta M., Saito H., Katano K., et al. A progressive postoperative increase in the serum level of soluble receptors for interleukin-2 is an indicator of a poor prognosis in patients with gastric cancer. Int J Mol Med 1 (1998) 113-116
157. Kikuyama S., Kubota T., Shimizu K., and Miyakita M. Ki-67 antigen expression in relation to clinicopathological variables and prognosis in gastric cancer. Oncol Rep 5 (1998) 867-870
158. Rugge M., Sonego F., Panozzo M., et al. Pathology and ploidy in the prognosis of gastric cancer with no extranodal metastasis. Cancer 73 (1994) 1127-1133
159. Yonemura Y., Fonseca L., Tsugawa K., et al. Prediction of lymph node metastasis and prognosis from the assay of the expression of proliferating cell nuclear antigen and DNA ploidy in gastric cancer. Oncology 51 (1994) 251-257
160. Kimura H., and Yonemura Y. Flow cytometric analysis of nuclear DNA content in advanced gastric cancer and its relationship with prognosis. Cancer 67 (1991) 2588-2593
161. Abad M., Ciudad J., Rincon M.R., et al. DNA aneuploidy by flow cytometry is an independent prognostic factor in gastric cancer. Anal Cell Pathol 16 (1998) 223-231
162. Sendler A., Gilbertz K.P., Becker I., et al. Proliferation kinetics and prognosis in gastric cancer after resection. Eur J Cancer 37 (2001) 1635-1641
163. Catalano V., Baldelli A.M., Giordani P., and Cascinu S. Molecular markers predictive of response to chemotherapy in gastrointestinal tumors. Crit Rev Oncol Hematol 38 (2001) 93-104
164. Cascinu S., Graziano F., Del Ferro E., et al. Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma. Cancer 83 (1998) 1917-1922
165. Nakata B., Chung K.H., Ogawa M., et al. p53 protein overexpression as a predictor of the response to chemotherapy in gastric cancer. Surg Today 28 (1998) 595-598
166. Lenz H.J., Leichman C.G., Danenberg K.D., et al. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 14 (1996) 176-182
167. Yeh K.H., Shun C.T., Chen C.L., et al. High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy. Cancer 82 (1998) 1626-1631
168. Metzger R., Leichman C.G., Danenberg K.D., et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 16 (1998) 309-316
169. Maruyama K., Sasako M., Kinoshita T., Sano T., and Katai H. Surgical treatment for gastric cancer: the Japanese approach. Semin Oncol 23 (1996) 360-368
170. Gouzi J.L., Huguier M., Fagniez P.L., et al. Total versus subtotal gastrectomy for adenocarcinoma of the gastric antrum. A French prospective controlled study. Ann Surg 209 (1989) 162-166
171. Robertson C.S., Chung S.C., Woods S.D., et al. A prospective randomized trial comparing R1 subtotal gastrectomy with R3 total gastrectomy for antral cancer. Ann Surg 220 (1994) 176-182
172. Bozzetti F., Marubini E., Bonfanti G., et al. Total versus subtotal gastrectomy: surgical morbidity and mortality rates in a multicenter Italian randomized trial. The Italian Gastrointestinal Tumor Study Group. Ann Surg 226 (1997) 613-620
173. Bozzetti F., Marubini E., Bonfanti G., et al. Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group. Ann Surg 230 (1999) 170-178
174. Maruyama K., Okabayashi K., and Kinoshita T. Progress in gastric cancer surgery in Japan and its limits of radicality. World J Surg 11 (1987) 418-425
175. Dent D.M., Madden M.V., and Price S.K. Randomized comparison of R1 and R2 gastrectomy for gastric carcinoma. Br J Surg 75 (1988) 110-112
176. Cuschieri A., Weeden S., Fielding J., et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 79 (1999) 1522-1530
177. Bonenkamp J.J., Hermans J., Sasako M., and van de Velde C.J. Extended lymph-node dissection for gastric cancer. Dutch Gastric Cancer Group. N Engl J Med 340 (1999) 908-914
178. Cuschieri A., Fayers P., Fielding J., et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet 347 (1996) 995-999
179. Bonenkamp J.J., Songun I., Hermans J., et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 345 (1995) 745-748
180. Hartgrink H.H., van de Velde C.J., Putter H., et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol 22 (2004) 2069-2077
181. Roukos D.H., Lorenz M., and Encke A. Evidence of survival benefit of extended (D2) lymphadenectomy in western patients with gastric cancer based on a new concept: a prospective long-term follow-up study. Surgery 123 (1998) 573-578
182. Bunt A.M., Hermans J., Smit V.T., et al. Surgical/pathologic-stage migration confounds comparisons of gastric cancer survival rates between Japan and Western countries. J Clin Oncol 13 (1995) 19-25
183. Roukos DH. Therapeutic value of D2-resection in gastric cancer evaluated with a new concept. UICC Consensus Conference. In: Kim JP, Min JS, Mok YJ, editors. Proceedings of the 3rd International Gastric Cancer Congress, Seoul 1999. Bologna: Monduzzi Editore; 1999. p. 29-33.
184. Katai H., Maruyama K., Sasako M., and Sano T. Incidence of nodal metastasis around the superior border of the pancreas based on number of metastatic perigastric nodes. Gastric Cancer 1 (1998) 115-117
185. Maruyama K., and Kaminishi N. Committee of Nation-wide Registry, Japanese Gastric Cancer Association. Japanese experience: from data of nation-wide registry. Proceedings of the 3rd International Gastric Cancer Congress. Seoul, Korea, April 27-30 (1999) [abstract 82]
186. Smith J.W., Shiu M.H., Kelsey L., and Brennan M.F. Morbidity of radical lymphadenectomy in the curative resection of gastric carcinoma. Arch Surg 126 (1991) 1469-1473
187. Sue-Ling H.M., Johnston D., Martin I.G., et al. Gastric cancer: a curable disease in Britain. Br Med J 307 (1993) 591-596
188. Degiuli M., Sasako M., Ponti A., et al. Morbidity and mortality after D2
189. Brennan M.F. Lymph-node dissection for gastric cancer. N Engl J Med 340 (1999) 956-958
190. Allum W.H., Griffin S.M., Watson A., and Colin-Jones D. Guidelines for the management of oesophageal and gastric cancer. Gut 50 Suppl 5 (2002) v1-23
191. Kodera Y., Schwarz R.E., and Nakao A. Extended lymph node dissection in gastric carcinoma: where do we stand after the Dutch and British randomized trials?. J Am Coll Surg 195 (2002) 855-864
192. Roukos D.H. Current advances and changes in treatment strategy may improve survival and quality of life in patients with potentially curable gastric cancer. Ann Surg Oncol 6 (1999) 46-56
193. Wu C.W., Hsiung C.A., Lo S.S., et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol 7 (2006) 309-315
194. Sano T., Sasako M., Yamamoto S., et al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy-Japan Clinical Oncology Group study 9501. J Clin Oncol 22 (2004) 2767-2773
195. Sasako M., Sano T., Yamamoto S., et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 359 (2008) 453-462
196. Okajima K., and Isozaki H. Splenectomy for treatment of gastric cancer: Japanese experience. World J Surg 19 (1995) 537-540
197. Wanebo H.J., Kennedy B.J., Winchester D.P., Stewart A.K., and Fremgen A.M. Role of splenectomy in gastric cancer surgery: adverse effect of elective splenectomy on longterm survival. J Am Coll Surg 185 (1997) 177-184
198. Csendes A., Burdiles P., Rojas J., et al. A prospective randomized study comparing D2 total gastrectomy versus D2 total gastrectomy plus splenectomy in 187 patients with gastric carcinoma. Surgery 131 (2002) 401-407
199. Yu W., Choi G.S., and Chung H.Y. Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. Br J Surg 93 (2006) 559-563
200. Sasako M. Risk factors for surgical treatment in the Dutch Gastric Cancer Trial. Br J Surg 84 (1997) 1567-1571
201. Maruyama K., Sasako M., Kinoshita T., et al. Pancreas-preserving total gastrectomy for proximal gastric cancer. World J Surg 19 (1995) 532-536
202. Rougier P., Lasser P., Ducreux M., et al. Preoperative chemotherapy of locally advanced gastric cancer. Ann Oncol 5 Suppl 3 (1994) 59-68
203. American Society for Gastrointestinal Endoscopy. Role of endoscopic ultrasonography. Gastrointest Endosc 52 (2000) 852-859
204. Ajani J.A., Ota D.M., Jessup J.M., et al. Resectable gastric carcinoma. An evaluation of preoperative and postoperative chemotherapy. Cancer 68 (1991) 1501-1506
205. Leichman L., Silberman H., Leichman C.G., et al. Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: a University of Southern California pilot program. J Clin Oncol 10 (1992) 1933-1942
206. Ajani J.A., Mayer R.J., Ota D.M., et al. Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma. J Natl Cancer Inst 85 (1993) 1839-1844
207. Alexander H.R., Grem J.L., Hamilton J.M., et al. Thymidylate synthase protein expression. Cancer J Sci Am 1 (1995) 49
208. Ajani J.A., Mansfield P.F., Lynch P.M., et al. Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. J Clin Oncol 17 (1999) 2403-2411
209. Songun I., Keizer H.J., Hermans J., et al. Chemotherapy for operable gastric cancer: results of the Dutch randomised FAMTX trial. The Dutch Gastric Cancer Group (DGCG). Eur J Cancer 35 (1999) 558-562
210. Hartgrink H.H., van d V., Putter H., et al. Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. Eur J Surg Oncol 30 (2004) 643-649
211. Fujii K., Kosaki G., Tsuchiya S., et al. Randomized trial of preoperative adjuvant chemotherapy using oral 5-FU in operable gastric cancer. Proc Am Soc Clin Oncol, J Clin Oncol 18 Suppl (1999) 272
212. Cunningham D., Allum W.H., Stenning S.P., et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355 (2006) 11-20
213. Boige V., Pignon J., Saint-Aubert B., et al. Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. Proc Am Soc Clin Oncol 25 Suppl (2007) 4510
214. Ott K., Sendler A., Becker K., et al. Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study. Gastric Cancer 6 (2003) 159-167
215. Cascinu S., Labianca R., Graziano F., et al. Intensive weekly chemotherapy for locally advanced gastric cancer using 5-fluorouracil, cisplatin, epidoxorubicin, 6S-leucovorin, glutathione and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Br J Cancer 78 (1998) 390-393
216. Cascinu S., Scartozzi M., Labianca R., et al. High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable gastric cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Br J Cancer 90 (2004) 1521-1525
217. Kelsen D., Karpeh M., Schwartz G., et al. Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil. J Clin Oncol 14 (1996) 1818-1828
218. Schuhmacher C.H., Fink U., Bottcher K., et al. Neoadjuvant chemotherapy for locally advanced gastric cancer: a phase II study with etoposide, adriamycin and cisplatin. Ann Oncol 5 Suppl 8 (1994) 76a
219. Plukker J.T., Mulder N.H., Sleijfer D.T., Grond J., and Verschueren R.C. Chemotherapy and surgery for locally advanced cancer of the cardia and fundus: phase II study with methotrexate and 5-fluorouracil. Br J Surg 78 (1991) 955-958
220. Wilke H., Preusser P., Fink U., et al. Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin. J Clin Oncol 7 (1989) 1318-1326
221. Kang Y.K., Choi D.W., Im Y.H., et al. A phase III randomized comparison of neoadjuvant chemotherapy followed by surgery versus surgery for locally advanced stomach cancer. Proc Am Soc Clin Oncol, J Clin Oncol 15 Suppl (1996) 215
222. Yonemura Y., Sawa T., Kinoshita K., et al. Neoadjuvant chemotherapy for high-grade advanced gastric cancer. World J Surg 17 (1993) 256-261
223. Zhang Z.X., Gu X.Z., Yin W.B., et al. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC)-report on 370 patients. Int J Radiat Oncol Biol Phys 42 (1998) 929-934
224. Skoropad V., Berdov B., and Zagrebin V. Concentrated preoperative radiotherapy for resectable gastric cancer: 20-years follow-up of a randomized trial. J Surg Oncol 80 (2002) 72-78
225. Gouchi A., Orita K., Fuchimoto S., et al. Randomized control study of preoperative intratumoral injection of OK-432 in gastric cancer patient: ten years survival. Proc Am Soc Clin Oncol, J Clin Oncol 16 Suppl (1997) 263
226. Peters K.M., Beuth J., Ko H.L., et al. Preoperative immunostimulation with propionibacterium avidum KP-40 in patients with gastric carcinoma: a prospective randomized study. Onkologie 13 (1990) 124-127
227. Terashima M., Takagane A., Sasaki T., et al. A prospective randomized trial of preoperative immunotherapy using PSK for the treatment of gastric cancer. Proc Am Soc Clin Oncol, J Clin Oncol 17 Suppl (1998) 304
228. Longmire Jr. W.P., Kuzma J.W., and Dixon W.J. The use of triethylenethiophosphoramide as an adjuvant to the surgical treatment of gastric carcinoma. Ann Surg 167 (1968) 293-312
229. Serlin O., Wolkoff J.S., Amadeo J.M., and Keehn R.J. Use of 5-fluorodeoxyuridine (FUDR) as an adjuvant to the surgical management of carcinoma of the stomach. Cancer 24 (1969) 223-228
230. The Gastrointestinal Tumor Study Group. Controlled trial of adjuvant chemotherapy following curative resection for gastric cancer. Cancer 49 (1982) 1116-1122
231. Schlag P., Schreml W., Gaus W., et al. Adjuvant 5-fluorouracil and BCNU chemotherapy in gastric cancer: 3-year results. Recent Results Cancer Res 80 (1982) 277-283
232. Higgins G.A., Amadeo J.H., Smith D.E., Humphrey E.W., and Keehn R.J. Efficacy of prolonged intermittent therapy with combined 5-FU and methyl-CCNU following resection for gastric carcinoma. A Veterans Administration Surgical Oncology, Group report. Cancer 52 (1983) 1105-1112
233. Engstrom P.F., Lavin P.T., Douglass Jr. H.O., and Brunner K.W. Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients. Eastern Cooperative Oncology Group study (EST 3275). Cancer 55 (1985) 1868-1873
234. The Italian Gastrointestinal Tumor Study Group. Adjuvant treatments following curative resection for gastric cancer. Br J Surg 75 (1988) 1100-1104
235. Imanaga H., and Nakazato H. Results of surgery for gastric cancer and effect of adjuvant mitomycin C on cancer recurrence. World J Surg 2 (1977) 213-221
236. Nakajima T., Takahashi T., Takagi K., Kuno K., and Kajitani T. Comparison of 5-fluorouracil with ftorafur in adjuvant chemotherapies with combined inductive and maintenance therapies for gastric cancer. J Clin Oncol 2 (1984) 1366-1371
237. Yamamura Y., Nishimura M., Sakamoto J., et al. A randomized controlled trial of surgical adjuvant therapy with mitomycin C, 5-fluorouracil and OK-432 in patients with gastric cancer. Gan To Kagaku Ryoho 13 (1986) 2134-2140
238. Allum W.H., Hallissey M.T., and Kelly K.A. Adjuvant chemotherapy in operable gastric cancer. 5 year follow-up of first British Stomach Cancer Group trial. Lancet 1 (1989) 571-574
239. Nakajima T., Nashimoto A., Kitamura M., et al. Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Gastric Cancer Surgical Study Group. Lancet 354 (1999) 273-277
240. Nakajima T., Fukami A., Ohashi I., and Kajitani T. Long-term follow-up study of gastric cancer patients treated with surgery and adjuvant chemotherapy with mitomycin C. Int J Clin Pharmacol Biopharm 16 (1978) 209-216
241. Grau J.J., Estape J., Alcobendas F., et al. Positive results of adjuvant mitomycin-C in resected gastric cancer: a randomised trial on 134 patients. Eur J Cancer 29A (1993) 340-342
242. Estape J., Grau J.J., Lcobendas F., et al. Mitomycin C as an adjuvant treatment to resected gastric cancer. A 10-year follow-up. Ann Surg 213 (1991) 219-221
243. Carrato A., Diaz-Rubio E., Medrano J., et al. Phase III trial of surgery versus adjuvant chemotherapy with mitomycin C and tegafur plus uracil, starting within the first week after surgery, for gastric adenocarcinoma. Proc Am Soc Clin Oncol, J Clin Oncol 14 Suppl (1995) 198
244. Grau J.J., Estape J., Fuster J., et al. Randomized trial of adjuvant chemotherapy with mitomycin plus ftorafur versus mitomycin alone in resected locally advanced gastric cancer. J Clin Oncol 16 (1998) 1036-1039
245. Cirera L., Balil A., Batiste-Alentorn E., et al. Randomized clinical trial of adjuvant mitomycin plus tegafur in patients with resected stage III gastric cancer. J Clin Oncol 17 (1999) 3810-3815
246. Coombes R.C., Schein P.S., Chilvers C.E., et al. A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. International Collaborative Cancer Group. J Clin Oncol 8 (1990) 1362-1369
247. Hallissey M.T., Dunn J.A., Ward L.C., and Allum W.H. The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up. Lancet 343 (1994) 1309-1312
248. Lise M., Nitti D., Marchet A., et al. Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer. J Clin Oncol 13 (1995) 2757-2763
249. Macdonald J.S., Fleming T.R., Peterson R.F., et al. Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group study. Ann Surg Oncol 2 (1995) 488-494
250. Krook J.E., O'Connell M.J., Wieand H.S., et al. A prospective, randomized evaluation of intensive-course 5-fluorouracil plus doxorubicin as surgical adjuvant chemotherapy for resected gastric cancer. Cancer 67 (1991) 2454-2458
251. Neri B., de Leonardis V., Romano S., et al. Adjuvant chemotherapy after gastric resection in node-positive cancer patients: a multicentre randomised study. Br J Cancer 73 (1996) 549-552
252. Tsavaris N., Tentas K., Kosmidis P., et al. A randomized trial comparing adjuvant fluorouracil, epirubicin, and mitomycin with no treatment in operable gastric cancer. Chemotherapy 42 (1996) 220-226
253. Huguier M., Destroyes J.P., Baschet C., Le Henand F., and Bernard P.F. Gastric carcinoma treated by chemotherapy after resection: a controlled study. Am J Surg 139 (1980) 197-199
254. Ochiai T., Sato H., Sato H., et al. Randomly controlled study of chemotherapy versus chemoimmunotherapy in postoperative gastric cancer patients. Cancer Res 43 (1983) 3001-3007
255. Nitti D., Wils J., Dos Santos J.G., et al. Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG. Ann Oncol 17 (2006) 262-269
256. De Vita F., Giuliani F., Orditura M., et al. Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study). Ann Oncol 18 (2007) 1354-1358
257. Ducreux M., Nordlinger B., Ychou M., et al. Resected gastric adenocarcinoma: randomized trial of adjuvant chemotherapy with 5 FU-cisplatin (FUP). Final results of the FFCD 8801 trial. Proc Am Soc Clin Oncol, J Clin Oncol 19 Suppl (2000) 241
258. Bouche O., Ychou M., Burtin P., et al. Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Ann Oncol 16 (2005) 1488-1497
259. Bajetta E., Buzzoni R., Mariani L., et al. Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group. Ann Oncol 13 (2002) 299-307
260. Di Costanzo F., Gasperoni S., Manzione L., et al. Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. J Natl Cancer Inst 100 (2008) 388-398
261. Chipponi J., Huguier M., Pezet D., et al. Randomized trial of adjuvant chemotherapy after curative resection for gastric cancer. Am J Surg 187 (2004) 440-445
262. Cascinu S., Labianca R., Barone C., et al. Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. J Natl Cancer Inst 99 (2007) 601-607
263. Koizumi W., Kurihara M., Nakano S., and Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 58 (2000) 191-197
264. Sakuramoto S., Sasako M., Yamaguchi T., et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357 (2007) 1810-1820
265. Hermans J., Bonenkamp J.J., Boon M.C., et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 11 (1993) 1441-1447
266. Hermans J., and Bonenkamp H.J. In reply [letter]. J Clin Oncol 12 (1994) 879-880
267. Earle C.C., and Maroun J.A. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer 35 (1999) 1059-1064
268. Mari E., Floriani I., Tinazzi A., et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). Ann Oncol 11 (2000) 837-843
269. Panzini I., Gianni L., Fattori P.P., et al. Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori 88 (2002) 21-27
270. Hu J.K., Chen Z.X., Zhou Z.G., et al. Intravenous chemotherapy for resected gastric cancer: meta-analysis of randomized controlled trials. World J Gastroenterol 8 (2002) 1023-1028
271. Janunger K.G., Hafstrom L., and Glimelius B. Chemotherapy in gastric cancer: a review and updated meta-analysis. Eur J Surg 168 (2002) 597-608
272. Schiessel R., Funovics J., Schick B., et al. Adjuvant intraperitoneal cisplatin therapy in patients with operated gastric carcinoma: results of a randomized trial. Acta Med Austriaca 16 (1989) 68-69
273. Sautner T., Hofbauer F., Depisch D., Schiessel R., and Jakesz R. Adjuvant intraperitoneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer. J Clin Oncol 12 (1994) 970-974
274. Hagiwara A., Takahashi T., Kojima O., et al. Prophylaxis with carbon-adsorbed mitomycin against peritoneal recurrence of gastric cancer. Lancet 339 (1992) 629-631
275. Hamazoe R., Maeta M., and Kaibara N. Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study. Cancer 73 (1994) 2048-2052
276. Rosen H.R., Jatzko G., Repse S., et al. Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology. J Clin Oncol 16 (1998) 2733-2738
277. Yu W., Whang I., Suh I., et al. Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann Surg 228 (1998) 347-354
278. Yan T.D., Black D., Sugarbaker P.H., et al. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for advanced gastric cancer. Proc Am Soc Clin Oncol, J Clin Oncol 25 Suppl (2007) 4614
279. Kramling H.J., Wilkowski R., Duhmke E., et al. Adjuvant intraoperative radiotherapy of stomach carcinoma. Langenbecks Arch Chir Suppl Kongressbd 113 (1996) 211-213
280. Imaizumi M., Kondo T., Kamei H., and Ichihashi H. Cooperative study group on surgical adjuvant immunochemotherapy for prevention of postoperative recurrence of gastric cancer supported by the Ministry of Health and Welfare (Kondo's group). Gan To Kagaku Ryoho 17 (1990) 2397-2403
281. Popiela T., Zembala M., Oszacki J., and Jedrychowski W. A follow-up study on chemoimmunotherapy (5-fluorouracil and BCG) in advanced gastric cancer. Cancer Immunol Immunother 13 (1982) 182-184
282. Jakesz R., Dittrich C., Funovics J., et al. The effect of adjuvant chemotherapy in gastric carcinoma is dependent on tumor histology: 5-year results of a prospective randomized trial. Recent Results Cancer Res 110 (1988) 44-51
283. Kim J.P., Kwon O.J., Oh S.T., and Yang H.K. Results of surgery on 6589 gastric cancer patients and immunochemosurgery as the best treatment of advanced gastric cancer. Ann Surg 216 (1992) 269-278
284. Kim J.P. Recent advances in gastric cancer therapy with immunochemosurgery. Asian J Surg 20 (1997) 115-118
285. Sato Y., Kondo M., Kohashi S., et al. A randomized controlled study of immunochemotherapy with OK-432 after curative surgery for gastric cancer. J Immunother 27 (2004) 394-397
286. Nakazato H., Koike A., Saji S., Ogawa N., and Sakamoto J. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer. Lancet 343 (1994) 1122-1126
287. Kim S.Y., Park H.C., Yoon C., et al. OK-432 and 5-fluorouracil, doxorubicin, and mitomycin C (FAM-P) versus FAM chemotherapy in patients with curatively resected gastric carcinoma: a randomized Phase III trial. Cancer 83 (1998) 2054-2059
288. Dent D.M., Werner I.D., Novis B., Cheverton P., and Brice P. Prospective randomized trial of combined oncological therapy for gastric carcinoma. Cancer 44 (1979) 385-391
289. Moertel C.G., Childs D.S., O'Fallon J.R., et al. Combined 5-fluorouracil and radiation therapy as a surgical adjuvant for poor prognosis gastric carcinoma. J Clin Oncol 2 (1984) 1249-1254
290. Macdonald J.S., Smalley S.R., Benedetti J., et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345 (2001) 725-730
291. Hundahl S.A., Macdonald J.S., Benedetti J., and Fitzsimmons T. Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: the effect of undertreatment. Ann Surg Oncol 9 (2002) 278-286
292. Kim S., Lim D.H., Lee J., et al. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys 63 (2005) 1279-1285
293. Tsujitani S., Oka S., Saito H., et al. Less invasive surgery for early gastric cancer based on the low probability of lymph node metastasis. Surgery 125 (1999) 148-154
294. Sue-Ling H.M., Martin I., Griffith J., et al. Early gastric cancer: 46 cases treated in one surgical department. Gut 33 (1992) 1318-1322
295. Sano T., Sasako M., Kinoshita T., and Maruyama K. Recurrence of early gastric cancer. Follow-up of 1475 patients and review of the Japanese literature. Cancer 72 (1993) 3174-3178
296. Hochwald S.N., Kim S., Klimstra D.S., Brennan M.F., and Karpeh M.S. Analysis of 154 actual five-year survivors of gastric cancer. J Gastrointest Surg 4 (2000) 520-525
297. Nakamura K., Morisaki T., Sugitani A., et al. An early gastric carcinoma treatment strategy based on analysis of lymph node metastasis. Cancer 85 (1999) 1500-1505
298. Namieno T., Koito K., Higashi T., et al. Assessing the suitability of gastric carcinoma for limited resection: histologic differentiation of endoscopic biopsy. World J Surg 22 (1998) 865-868
299. Kunisaki C., Shimada H., Nomura M., and Akiyama H. Appropriate lymph node dissection for early gastric cancer based on lymph node metastases. Surgery 129 (2001) 153-157
300. Korenaga D., Haraguchi M., Tsujitani S., et al. Clinicopathological features of mucosal carcinoma of the stomach with lymph node metastasis in eleven patients. Br J Surg 73 (1986) 431-433
301. Iriyama K., Asakawa T., Koike H., Nishiwaki H., and Suzuki H. Is extensive lymphadenectomy necessary for surgical treatment of intramucosal carcinoma of the stomach?. Arch Surg 124 (1989) 309-311
302. Kofuji K., Takeda J., Toyonaga A., et al. Early gastric cancer and lymph node metastasis. Kurume Med J 44 (1997) 157-164
303. Gotoda T., Yanagisawa A., Sasako M., et al. Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. Gastric Cancer 3 (2000) 219-225
304. Yamao T., Shirao K., Ono H., et al. Risk factors for lymph node metastasis from intramucosal gastric carcinoma. Cancer 77 (1996) 602-606
305. Yamada H., Nihei Z., Yamashita T., et al. Is lymphadenectomy needed for all submucosal gastric cancers?. Eur J Surg 167 (2001) 199-203
306. Yasuda K., Shiraishi N., Suematsu T., et al. Rate of detection of lymph node metastasis is correlated with the depth of submucosal invasion in early stage gastric carcinoma. Cancer 85 (1999) 2119-2123
307. Kurihara N., Kubota T., Otani Y., et al. Lymph node metastasis of early gastric cancer with submucosal invasion. Br J Surg 85 (1998) 835-839
308. Japanese Gastric Cancer Association. Treatment guidelines for gastric cancer in Japan (in Japanese). 2nd ed. (2004), Japanese Gastric Cancer Association, Tokyo
309. Uedo N., Ishii H., Tatsuta M., et al. Long-term outcomes after endoscopic mucosal resection for early gastric cancer. Gastric Cancer 9 (2006) 88-92
310. Ahmadi A., and Draganov P. Endoscopic mucosal resection in the upper gastrointestinal tract. World J Gastroenterol 14 (2008) 1984-1989
311. Tanaka M., Ono H., Hasuike N., and Takizawa K. Endoscopic submucosal dissection of early gastric cancer. Digestion 77 Suppl 1 (2008) 23-28
312. Ono H. Early gastric cancer: diagnosis, pathology, treatment techniques and treatment outcomes. Eur J Gastroenterol Hepatol 18 (2006) 863-866
313. Sasako M. Principles of surgical treatment for curable gastric cancer. J Clin Oncol 21 (2003) 274s-275s
314. Fuchs C.S., and Mayer R.J. Gastric carcinoma. New Engl J Med 333 (1995) 32-41
315. Davis P.A., and Sano T. The difference in gastric cancer between Japan, USA and Europe: What are the facts? What are the suggestions?. Crit Rev Oncol Hematol 40 (2001) 77-94
316. Blot W.J., Devesa S.S., Kneller R.W., and Fraumeni J.F. Rising incidence of adenocarcinoma of the oesophagus and gastric cardia. J Am Med Assoc 265 (1991) 1287-1289
317. Powel J., and McConkey C.C. Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites. Br J Cancer 62 (1990) 440-443
318. McCulloch P. Gastric cancer. Postgrad Med J 72 (1996) 450-457
319. Hundahl S.A., Phillips J.L., and Menck H.R. The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the 'different disease' hypothesis. Cancer 88 (2000) 921-932
320. Bonenkamp J.J., van de Velde C.J., Kampschoer G.H., et al. Comparison of factors influencing the prognosis of Japanese, German, and Dutch gastric cancer patients. World J Surg 17 (1993) 410-414
321. Adachi W., Kobayashi M., Koike S., et al. The influence of excess body weight on the surgical treatment of patients with gastric cancer. Surg Today 25 (1995) 939-945
322. Comis S. Integration of chemotherapy into combined modality treatment of solid tumors. Cancer Treat Rep 1 (1974) 22-23
323. Cocconi G., DeLisi V., and Di Blasio B. Randomized comparison of 5-FU alone or combined with mitomycin and cytarabine (MFC) in the treatment of advanced gastric cancer. Cancer Treat Rep 66 (1982) 1263-1266
324. Hill M.E., and Cunningham D. Medical management of advanced gastric cancer. Cancer Treat Rev 24 (1998) 113-118
325. Schoffski P. New drugs for treatment of gastric cancer. Ann Oncol 13 Suppl 4 (2002) 13-22
326. Baker L.H., Talley R.W., Matter R., et al. Phase III comparison of the treatment of advanced gastrointestinal cancer with bolus weekly 5-FU vs. methyl-CCNU plus bolus weekly 5-FU. A Southwest Oncology Group study. Cancer 38 (1976) 1-7
327. Levi J.A., Fox R.M., Tattersall M.H., et al. Analysis of a prospectively randomized comparison of doxorubicin versus 5-fluorouracil, doxorubicin, and BCNU in advanced gastric cancer: implications for future studies. J Clin Oncol 4 (1986) 1348-1355
328. Schnitzler G., Queisser W., Heim M.E., et al. Phase III study of 5-FU and carmustine versus 5-FU, carmustine, and doxorubicin in advanced gastric cancer. Cancer Treat Rep 70 (1986) 477-479
329. Macdonald J.S., Schein P.S., Woolley P.V., et al. 5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med 93 (1980) 533-536
330. Douglass Jr. H.O., Lavin P.T., Goudsmit A., Klaassen D.J., and Paul A.R. An Eastern Cooperative Oncology Group evaluation of combinations of methyl-CCNU, mitomycin C, Adriamycin, and 5-fluorouracil in advanced measurable gastric cancer (EST 2277). J Clin Oncol 2 (1984) 1372-1381
331. Cullinan S.A., Moertel C.G., Fleming T.R., et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs. fluorouracil and doxorubicin vs. fluorouracil, doxorubicin, and mitomycin. JAMA 253 (1985) 2061-2067
332. Klein H.O., Wickramanayake P.D., Dieterle F., et al. High-dose MTX/5-FU and adriamycin for gastric cancer. Semin Oncol 10 (1983) 29-31
333. Wils J.A., Klein H.O., Wagener D.J., et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin-a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 9 (1991) 827-831
334. Wilke H., Preusser P., Fink U., et al. New developments in the treatment of gastric carcinoma. Semin Oncol 17 (1990) 61-70
335. Preusser P., Wilke H., Achterrath W., et al. Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol 7 (1989) 1310-1317
336. Kelsen D., Atiq O.T., Saltz L., et al. FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol 10 (1992) 541-548
337. O'Connell M.J. Etoposide, doxorubicin, and cisplatin chemotherapy for advanced gastric cancer: an old lesson revisited. J Clin Oncol 10 (1992) 515-516
338. Kim N.K., Park Y.S., Heo D.S., et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 71 (1993) 3813-3818
339. Icli F., Celik I., Aykan F., et al. A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma. Turkish Oncology Group. Cancer 83 (1998) 2475-2480
340. Vanhoefer U., Rougier P., Wilke H., et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 18 (2000) 2648-2657
341. Findlay M., Cunningham D., Norman A., et al. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 5 (1994) 609-616
342. Webb A., Cunningham D., Scarffe J.H., et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15 (1997) 261-267
343. Waters J.S., Norman A., Cunningham D., et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer 80 (1999) 269-272
344. Ross P., Nicolson M., Cunningham D., et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 20 (2002) 1996-2004
345. Cocconi G., Bella M., Zironi S., et al. Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 12 (1994) 2687-2693
346. Cocconi G., Carlini P., Gamboni A., et al. Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma. Ann Oncol 14 (2003) 1258-1263
347. Cascinu S., Labianca R., Alessandroni P., et al. Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer. J Clin Oncol 15 (1997) 3313-3319
348. Louvet C., Andre T., Tigaud J.M., et al. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 20 (2002) 4543-4548
349. De Vita F., Orditura M., Matano E., et al. A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer 92 (2005) 1644-1649
350. Lordick F., Lorenzen S., Stollfuss J., et al. Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer. Br J Cancer 93 (2005) 190-194
351. Ajani J.A., Becker I., Pisters P.W., et al. Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma. Oncology (Huntingt) 16 Suppl 5 (2002) 16-18
352. Roth A.D., Maibach R., Martinelli G., et al. Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Ann Oncol 11 (2000) 301-306
353. Bouche O., Raoul J.L., Bonnetain F., et al. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study-FFCD 9803. J Clin Oncol 22 (2004) 4319-4328
354. Pozzo C., Barone C., Szanto J., et al. Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study. Ann Oncol 15 (2004) 1773-1781
355. Cunningham D., Starling N., Rao S., et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358 (2008) 36-46
356. Kang Y., Kang W.K., Shin D.B., et al. Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): efficacy and safety results. Proc Am Soc Clin Oncol, J Clin Oncol 24 Suppl (2006) LBA4018
357. Koizumi W., Narahara H., Hara T., et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9 (2008) 215-221
358. Boku N., Yamamoto S., Shirao K., et al. Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912). Proc Am Soc Clin Oncol, J Clin Oncol 25 Suppl (2007) LBA4513
359. Al-Batran S.E., Hartmann J.T., Probst S., et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 26 (2008) 1435-1442
360. Dank M., Zaluski J., Barone C., et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naïve patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 19 (2008) 1450-1457
361. Van Cutsem E., Moiseyenko V.M., Tjulandin S., et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24 (2006) 4991-4997
362. Ajani J.A., Moiseyenko V.M., Tjulandin S., et al. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. J Clin Oncol 25 (2007) 3210-3216
363. Ajani J.A., Moiseyenko V.M., Tjulandin S., et al. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol 25 (2007) 3205-3209
364. Wagner A.D., Grothe W., Haerting J., et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24 (2006) 2903-2909
365. Wagner A.D., Grothe W., Haerting J., et al. Combination chemotherapies in advanced gastric cancer: An updated systematic review and meta-analysis. Proc Am Soc Clin Oncol, J Clin Oncol 25 Suppl (2007) 4555
366. Shah M.A., Ramanathan R.K., Ilson D.H., et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 24 33 (2006) 5201-5206
367. Pinto C., Di F.F., Siena S., et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 18 (2007) 510-517
368. Murad A.M., Santiago F.F., Petroianu A., et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72 (1993) 37-41
369. Pyrhonen S., Kuitunen T., Nyandoto P., and Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71 (1995) 587-591
370. Scheitauer W., Kornek G., Zeh B., et al. Palliative chemotherapy versus supportive care in patients with metastatic gastric cancer: a randomized trial. Proceedings of the Second International Conference on Biology, Prevention and Treatment of GI Malignancy. Koln, Germany (1995)
371. Glimelius B., Ekstrom K., Hoffman K., et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8 (1997) 163-168
372. Ringdal G.I., and Ringdal K. Testing the EORTC Quality of Life Questionnaire on cancer patients with heterogeneous diagnoses. Qual Life Res 2 (1993) 129-140
373. Hjermstad M.J., Fossa S.D., Bjordal K., and Kaasa S. Test/retest study of the European organization for research and treatment of cancer core quality-of-life questionnaire. J Clin Oncol 13 (1995) 1249-1254
374. Ouchi K., Sugawara T., Ono H., et al. Therapeutic significance of palliative operations for gastric cancer for survival and quality of life. J Surg Oncol 69 (1998) 41-44
375. Isozaki H., Okajima K., Kawashima Y., et al. Relative non-curative resection of gastric cancer: a review of 106 cases. Jpn J Cancer Clin 39 (1993) 657-662
376. Maekawa S., Saku M., Maehara Y., et al. Surgical treatment for advanced gastric cancer. Hepatogastroenterology 43 (1996) 178-186
377. Bozzetti F., Bonfanti G., Audisio R.A., et al. Prognosis of patients after palliative surgical procedures for carcinoma of the stomach. Surg Gynecol Obstet 164 (1987) 151-154
378. Haugstvedt T., Viste A., Eide G.E., and Soreide O. The survival benefit of resection in patients with advanced stomach cancer: the Norwegian multicenter experience. Norwegian Stomach Cancer Trial. World J Surg 13 (1989) 617-621
379. Meijer S., De Bakker O.J., and Hoitsma H.F. Palliative resection in gastric cancer. J Surg Oncol 23 (1983) 77-80
380. Monson J.R., Donohue J.H., McIlrath D.C., Farnell M.B., and Ilstrup D.M. Total gastrectomy for advanced cancer. A worthwhile palliative procedure. Cancer 68 (1991) 1863-1868
381. Ekbom G.A., and Gleysteen J.J. Gastric malignancy: resection for palliation. Surgery 88 (1980) 476-481
382. Thompson G.B., van Heerden J.A., and Sarr M.G. Adenocarcinoma of the stomach: are we making progress?. Lancet 342 (1993) 713-718
383. Hartgrink H.H., Putter H., Klein K.E., Bonenkamp J.J., and van de Velde C.J. Value of palliative resection in gastric cancer. Br J Surg 89 (2002) 1438-1443
384. Kikuchi S., Arai Y., Morise M., et al. Gastric cancer with metastases to the distant peritoneum: a 20-year surgical experience. Hepatogastroenterology 45 (1998) 1183-1188
385. Cuschieri A. Laparoscopic management of cancer patients. J R Coll Surg Edinb 40 (1995) 1-9
386. Moertel C.G., Childs Jr. D.S., Reitemeier R.J., Colby Jr. M.Y., and Holbrook M.A. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 2 (1969) 865-867
387. Falkson G., and van Eden E.B. A controlled clinical trial of fluorouracil plus imidazole carboxamide dimethyl triazeno plus vincristine plus bis-chloroethyl nitrosourea plus radiotherapy in stomach cancer. Med Pediatr Oncol 2 (1976) 111-117
388. Klaassen D.J., MacIntyre J.M., Catton G.E., Engstrom P.F., and Moertel C.G. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil-an Eastern Cooperative Oncology Group study. J Clin Oncol 3 (1985) 373-378
389. Mantell B.S. Radiotherapy for dysphagia due to gastric carcinoma. Br J Surg 69 (1982) 69-70
390. Loizou L.A., Rampton D., Atkinson M., Robertson C., and Bown S.G. A prospective assessment of quality of life after endoscopic intubation and laser therapy for malignant dysphagia. Cancer 70 (1992) 386-391
391. Knyrim K., Wagner H.J., Bethge N., Keymling M., and Vakil N. A controlled trial of an expansile metal stent for palliation of esophageal obstruction due to inoperable cancer. N Engl J Med 329 (1993) 1302-1307
392. Cusumano A., Ruol A., Segalin A., et al. Push-through intubation: effective palliation in 409 patients with cancer of the esophagus and cardia. Ann Thorac Surg 53 (1992) 1010-1014
393. Gunderson L.L., and Sosin H. Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 8 (1982) 1-11
394. Ambiru S., Miyazaki M., Ito H., et al. Benefits and limits of hepatic resection for gastric metastases. Am J Surg 181 (2001) 279-283
395. Okano K., Maeba T., Ishimura K., et al. Hepatic resection for metastatic tumors from gastric cancer. Ann Surg 235 (2002) 86-91
396. Ochiai T., Sasako M., Mizuno S., et al. Hepatic resection for metastatic tumours from gastric cancer: analysis of prognostic factors. Br J Surg 81 (1994) 1175-1178
397. Bines S.D., England G., Deziel D.J., et al. Synchronous, metachronous, and multiple hepatic resections of liver tumors originating from primary gastric tumors. Surgery 114 (1993) 799-805
398. Saito A., Korenaga D., Sakaguchi Y., et al. Surgical treatment for gastric carcinomas with concomitant hepatic metastasis. Hepatogastroenterology 43 (1996) 560-564
399. Wu C.W., Lo S.S., Shen K.H., et al. Incidence and factors associated with recurrence patterns after intended curative surgery for gastric cancer. World J Surg 27 (2003) 153-158
400. Shiraishi N., Inomata M., Osawa N., et al. Early and late recurrence after gastrectomy for gastric carcinoma, Univariate and multivariate analyses. Cancer 89 (2000) 255-261
401. Landry J., Tepper J.E., Wood W.C., et al. Patterns of failure following curative resection of gastric carcinoma. Int J Radiat Oncol Biol Phys 19 (1990) 1357-1362
402. Katai H., Maruyama K., Sasako M., et al. Mode of recurrence after gastric cancer surgery. Dig Surg 11 (1994) 99-103
403. Yoo C.H., Noh S.H., Shin D.W., Choi S.H., and Min J.S. Recurrence following curative resection for gastric carcinoma. Br J Surg 87 (2000) 236-242
404. Lacueva F.J., Calpena R., Medrano J., et al. Follow-up of patients resected for gastric cancer. J Surg Oncol 60 (1995) 174-179
405. Huguier M., Houry S., and Lacaine F. Is the follow-up of patients operated on for gastric carcinoma of benefit to the patient?. Hepatogastroenterology 39 (1992) 14-16
406. Bohner H., Zimmer T., Hopfenmuller W., Berger G., and Buhr H.J. Detection and prognosis of recurrent gastric cancer--is routine follow-up after gastrectomy worthwhile?. Hepatogastroenterology 47 (2000) 1489-1494